Novartis signaled an expanded commitment to RNA interference (RNAi) as a therapeutic modality, with CEO Vas Narasimhan describing a deliberate, de‑risking approach to build on recent modality wins. The company framed RNAi as the next strategic platform after radioligands and autoimmune CAR‑T initiatives, citing modular scalability and pipeline fit. Novartis’ public comments outline greater resource allocation and partnering to accelerate RNAi programs. The move reflects large pharma positioning behind second‑generation modalities where prior clinical and commercial validation reduces development risk.